Non-pharmacologic treatment

Cook MJ et al. Rheumatology (Oxford) 2018: key224. doi: 10.1093/rheumatology/key224

Merz EL, Assassi S, Malcarne VL. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0104-4

Compagnoni R, Gualtierotti R, Randelli P. Adv Ther 2018. doi: 10.1007/s12325-018-0750-9

Jabari D et al. Curr Rheumatol Rep 2018; 20: 52. doi: 10.1007/s11926-018-0755-z

Bellocchi C, Volkmann ER. Curr Rheumatol Rep 2018; 20: 49. doi: 10.1007/s11926-018-0758-9

Castro LL et al. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4169-0

In this piece, Sarah Patterson and Patricia Katz discuss the benefits of exercise, and the barriers to increasing physical activity, in patients with systemic lupus erythematosus.

Mitropoulos A et al. Arthritis Res Ther 2018; 20: 112. doi: 10.1186/s13075-018-1605-0

Results of a randomized controlled trial suggest that an internet-based self-management program is no more beneficial than an educational book for patients with systemic sclerosis.

Abad TO et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4031-3

Geenen R et al. Ann Rheum Dis 2018; 77: 797–807. doi: 10.1136/annrheumdis-2017-212662

Miller FW et al. Nat Rev Rheumatol 2018; 14: 255–268. doi: 10.1038/nrrheum.2018.48

Rider LG et al. Nat Rev Rheumatol 2018; 14: 303–318. doi: 10.1038/nrrheum.2018.33

Barturen G et al. Nat Rev Rheumatol 2018; 14: 75–93. doi: 10.1038/nrrheum.2017.220

Editorial Board member Oliver FitzGerald reviews the recent guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.

The authors review the evidence for the effects of several common dietary components on rheumatic diseases, suggesting a common denominator: these bioactive compounds have a role in shaping our gut microbiome.

Nat Rev Rheumatol 2017;13:348–358. doi:10.1038/nrrheum.2017.42

Kasturi and Goodman evaluate the rates, outcomes, and adverse events associated with arthroplasty in systemic lupus erythematosus patients who are at increased risk of joint damage.

Kasturi S & Goodman S. Curr Rheumatol Rep 2016;18:59. doi:10.1007/s11926-016-0608-6

Despite improved prognosis, systemic lupus erythematosus therapies are still associated with treatment-related complications. This chapter reviews these issues in non-pharmacologic and pharmacologic therapies.

Quattrocchio G et al. In: Connective Tissue Disease. Edited by Roccatello D & Emmi L. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-24535-5_16

This paper discusses potential mechanisms linking rheumatoid arthritis and increased cardiovascular disease risk, with a focus on inflammation, and highlights the need for cardiovascular risk assessment and management in patients with rheumatoid arthritis.

Nat Rev Rheumatol 2015; 11: 693–704. doi:10.1038/nrrheum.2015.112